Arrestin-β-1 Physically Scaffolds TSH and IGF1 Receptors to Enable Crosstalk-Reference-Cited by-同舟云学术

Arrestin-β-1 Physically Scaffolds TSH and IGF1 Receptors to Enable Crosstalk

Published:2019-04-26 Issue:6 Volume:160 Page:1468-1479
ISSN:1945-7170
Container-title:Endocrinology
language:en
Short-container-title:

Author:

Krieger Christine C¹^ORCID,Boutin Alisa¹,Jang Daesong¹,Morgan Sarah J¹,Banga J Paul²,Kahaly George J³,Klubo-Gwiezdzinska Joanna⁴,Neumann Susanne¹,Gershengorn Marvin C¹

Affiliation:

1. Laboratory of Endocrinology and Receptor Biology, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland

2. Faculty of Life Sciences & Medicine, King’s College London, The Rayne Institute, London, United Kingdom

3. Molecular Thyroid Research Laboratory, Department of Medicine I, Johannes Gutenberg University Medical Center, Mainz, Germany

4. Metabolic Disease Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland

Funder

National Institute of Diabetes and Digestive and Kidney Diseases

Publisher

The Endocrine Society

Subject

Endocrinology

Link

http://academic.oup.com/endo/advance-article-pdf/doi/10.1210/en.2019-00055/28521135/en.2019-00055.pdf

Reference43 articles.

1. Graves’ ophthalmopathy;Bahn;N Engl J Med,2010

2. Current insights into the pathogenesis of Graves’ ophthalmopathy;Bahn;Horm Metab Res,2015

3. Current perspectives on the role of orbital fibroblasts in the pathogenesis of Graves’ ophthalmopathy;Dik;Exp Eye Res,2016

4. Bidirectional TSH and IGF-1 receptor cross talk mediates stimulation of hyaluronan secretion by Graves’ disease immunoglobins;Krieger;J Clin Endocrinol Metab,2015

5. A stimulatory thyrotropin receptor antibody enhances hyaluronic acid synthesis in graves’ orbital fibroblasts: inhibition by an IGF-I receptor blocking antibody;Kumar;J Clin Endocrinol Metab,2012

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of teprotumumab and role of HLA markers in patients with thyroid eye disease;Endocrine Practice;2024-08

2. Low molecular inverse agonist of the thyrotropin receptor is active both intraperitoneal and oral administration;Российский физиологический журнал им И М Сеченова;2024-06-28

3. Low Molecular Weight Thyrotropin Receptor Inverse Agonist Is Active upon Both Intraperitoneal and Oral Administration;Journal of Evolutionary Biochemistry and Physiology;2024-01

4. Linsitinib, an IGF-1R inhibitor, attenuates disease development and progression in a model of thyroid eye disease;Frontiers in Endocrinology;2023-06-26

5. A review of TSHR- and IGF-1R-related pathogenesis and treatment of Graves’ orbitopathy;Frontiers in Immunology;2023-01-19